Elicio Therapeutics and Angion enter into merger agreement to advance cancer vaccine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Elicio Therapeutics has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network, and Fred Hutchinson Cancer Center. 

Login